Azienda Unita Sanitaria Locale Di Bologna

At Azienda Unita Sanitaria Locale Di Bologna, the neurology team is involved in clinical research on H3 K27M-mutant diffuse glioma, focusing on brain tumors within the broader field of neoplasms. These studies are designed to assess whether new treatment approaches can improve outcomes after standard care and support better disease control.

• Evaluating a new therapy for H3 K27M-mutant diffuse glioma after radiotherapy
• Studying treatment effectiveness in a rare and aggressive brain tumor
• Advancing care in neuro-oncology through targeted research

This work reflects a strong interest in improving options for patients with difficult-to-treat central nervous system cancers.

Clinical trials at this site also address ischemic stroke prevention, including patients recovering from an acute non-cardioembolic stroke or those at high risk after a transient ischemic attack. Research in this cardiovascular area is aimed at reducing the chance of another stroke while also assessing safety and overall treatment benefit.

• Preventing recurrent ischemic stroke after a recent event
• Evaluating whether a new oral treatment can improve protection beyond standard antiplatelet therapy
• Monitoring safety outcomes, including major bleeding risk

These studies support better long-term management of patients with high vascular risk and a history of stroke-related events.

The research portfolio at Azienda Unita Sanitaria Locale Di Bologna includes studies in Huntington’s disease, a progressive inherited neurological disorder. The trials are exploring both long-term safety and biological effects of a potential therapy, with the goal of better understanding how to slow or modify the disease process.

• Assessing the long-term safety of an investigational treatment for Huntington’s disease
• Measuring changes in disease-related biomarkers linked to huntingtin levels
• Supporting research into inherited neurological disorders

This area of research is especially important for families affected by rare genetic conditions, where new therapeutic options are still urgently needed.